RADX: Prakiraan konsensus analis Radiopharm Theranostics Ltd

Radiopharm Theranostics (RADX) is a biotech player developing nuclear oncology therapeutics, whose isotope patents ensure a long-term moat against competitors. The business relies on platform licensing, which generates high profits alongside stable costs. Demand for targeted tumor destruction is rising, and the alpha-therapy market is expanding. The current metric is 12.73. Financial price visualization on GURU.Markets is available below.

RADX (radiopharmtheranostics.com) riwayat Target konsensus saka 06.12.2024 nganti 22.10.2026

Rincian analitis perusahaan Radiopharm Theranostics Limited (RADX)

Indikator analitis utama Radiopharm Theranostics Ltd (RADX):

Bagan owah-owahan rega radiopharmtheranostics.com|RADX - Prakiraan konsensus analis|Kapitalisasi pasar Radiopharm Theranostics

Analisis fundamental perusahaan:radiopharmtheranostics.com (RADX)

Produk asli Radiopharm Theranostics Limited

Investors are verifying the reliability of Radiopharm Theranostics (RADX) through multiples, weighing the capital expenditures required for the complex logistics of short-lived isotopes against the capitalization potential. The average value of 12.73, displayed as the expert-forecasted share price, represents the averaged target from investment houses, allowing for an assessment of the fundamental upside and preventing the freezing of funds in a low-liquidity asset during periods of excessive optimism.

Perusahaan pesaing

ONC (beigene.com) - Konsensus nilai wajar|Prakiraan konsensus analis HALO (Halozyme)|Prakiraan konsensus analis Revolution Medicines Inc RVMD|Ascentage - Prakiraan konsensus analis|CGON (CG Oncology Therapeutics) - Prakiraan gabungan firma investasi|URGN (UroGen Pharma Ltd.) - Target konsensus|Prakiraan gabungan firma investasi BCAX|PSNL (Personalis) - Prakiraan konsensus analis|Target konsensus Erasca Inc (ERAS)|Prakiraan konsensus analis DCTH|Prakiraan konsensus analis Y-mAbs Corp (YMAB)|Bagan rega target Aura Biosciences, Inc. AURA|CADL: Prakiraan gabungan firma investasi|Accuray - Prakiraan konsensus analis|SELLAS Life Sciences (SLS) - Target konsensus|ACTU: Prakiraan konsensus analis|Rata-rata rega prakiraan Citius Oncology Inc (CTOR)|Bagan rega target TuHURA Biosciences Inc.|TARA: Konsensus nilai wajar|Target konsensus FATE (Fate Therapeutics)|WHWK (aadibio.com) - Konsensus nilai wajar|Prakiraan konsensus analis TCRX (TScan Therapeutics, Inc.)|CSBR - Target konsensus|XBIT: Target konsensus|CVM - Prakiraan konsensus analis|OS Therapies (OSTX) - Bagan rega target|Artiva Biotherapeutics - Konsensus nilai wajar|ANL (Adlai Nortye Ltd) - Prakiraan konsensus analis|Rata-rata rega prakiraan Veru Corporation VERU|Bagan rega target Tempest Therapeutics (TPST)|XLO (xiliotx.com) - Konsensus nilai wajar|Prakiraan konsensus analis RENB (Renovaro)|Prakiraan konsensus analis Mural Oncology PLC MURA|Kairos Pharma Inc - Prakiraan konsensus analis|OKUR (OnKure Therapeutics Inc) - Prakiraan gabungan firma investasi|GDTC: Prakiraan konsensus analis|CRIS - Target median analis|Bagan rega target Apollomics Inc.|Rata-rata rega prakiraan Tharimmune Inc THAR|Bagan rega target Advanced Biomed Inc (ADVB)|GNPX: Bagan tingkat prakiraan|Prakiraan konsensus analis CLDI (Calidi Biotherapeutics, Inc.)|Konsensus nilai wajar SBFM|Xenetic Bio - Prakiraan konsensus analis|SLRX - Prakiraan konsensus analis|Purple Biotech Corp (PPBT) - Bagan rega target|American Oncology Network, Inc. - Konsensus nilai wajar|Bagan rega target BeiGene, Ltd.|Target konsensus checkpointtx.com (CKPT)|Target konsensus ELEV (Elevation Oncology, Inc.)|ICAD (icadmed.com) - Konsensus nilai wajar|Ikena Oncology - Target konsensus|Rega prakiraan analis NTBL (Notable Labs Corp)|Viracta - Prakiraan konsensus analis|Konsensus nilai wajar MOR (morphosys.com)|NAYA: Prakiraan konsensus analis|Rata-rata rega prakiraan Ascentage Pharma Group International (AAPGV)